Neurocrine Biosciences Inc $ 97.05 -0.65 (-0.67%)
Volume:
235,955
Avg Vol (1m):
791,481
Market Cap $:
9.01 Bil
Enterprise Value $:
8.56 Bil
P/E (TTM):
45.78
P/B:
10.84
Financial Strength | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1.88 | ||
| Equity-to-Asset | 0.55 | ||
| Debt-to-Equity | 0.61 | ||
| Debt-to-EBITDA | 1.94 | ||
| Interest Coverage | 10.91 | ||
| Piotroski F-Score | 7 | ||
| Altman Z-Score | 8.71 | ||
| Beneish M-Score | -2.1 | ||
| WACC vs ROIC | |||
Profitability Rank | 2/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 35.45 | ||
| Net Margin % | 20.36 | ||
| ROE % | 31.73 | ||
| ROA % | 15.92 | ||
| ROC (Joel Greenblatt) % | 178.47 | ||
| 3-Year Revenue Growth Rate | 262.4 |
NBIX
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 45.78 | ||
| Forward PE Ratio | 22.07 | ||
| PE Ratio without NRI | 45.78 | ||
| Price-to-Owner-Earnings | 49.47 | ||
| PB Ratio | 10.84 | ||
| PS Ratio | 9.34 | ||
| Price-to-Free-Cash-Flow | 27.19 | ||
| Price-to-Operating-Cash-Flow | 26.26 | ||
| EV-to-EBIT | 34 | ||
| EV-to-EBITDA | 32.92 | ||
| EV-to-Revenue | 8.52 | ||
| Current Ratio | 2 | ||
| Quick Ratio | 1.96 | ||
| Days Inventory | 661.65 | ||
| Days Sales Outstanding | 53.86 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 875.68 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 11.85 | ||
| Price-to-Graham-Number | 4.69 | ||
| Earnings Yield (Greenblatt) % | 2.94 |